Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUO-E phase 3 trial of durvalumab with chemotherapy followed by durvalumab maintenance with or without olaparib in advanced or recurrent endometrial cancer
MOH_2020-09-16_009136Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of durvalumab and olaparib in endometrial cancer (EC) (3 arms), sponsored by AstraZeneca. Started Sep 2020; status: recruiting.
02
Drugs
durvalumabolaparib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on MOH_2020-09-16_009136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-09-16_009136.